Elsevier

Clinical Oncology

Volume 24, Issue 3, April 2012, Pages 208-215
Clinical Oncology

Original Article
Adaptive Radiotherapy Using Helical Tomotherapy for Head and Neck Cancer in Definitive and Postoperative Settings: Initial Results

https://doi.org/10.1016/j.clon.2011.11.005Get rights and content

Abstract

Aims

To assess whether routine mid-treatment replanning in head and neck squamous cell carcinoma patients results in meaningful improvements in target or normal tissue dosimetry and to assess which patients derive the greatest benefit.

Materials and methods

Twenty patients treated with either postoperative chemoradiotherapy or definitive chemoradiotherapy with primary or nodal disease ≥3 cm in size were included in this prospective pilot study. Seven patients received adjuvant chemoradiotherapy and 13 received definitive chemoradiotherapy. Patients were planned and treated on a helical tomotherapy system. All patients had a second computed tomography scan after 15 fractions and a new plan based on this was initiated from fraction 20.

Results

Relative volume changes between computed tomography scans were: GTV 29%; CTV60 (adjuvant patients) 4%; parotid volume 17.5%; median reduction in neck separation 6–7 mm; weight loss 3%. For the group overall and for the definitively treated patient cohort, respectively, adapted plans resulted in reductions in PTV66 D1 (0.3 Gy, P = 0.01 and 0.5 Gy, P = 0.01); PTV54 D1 (0.6 Gy, P < 0.0001 and 0.9 Gy, P = 0.0002); spinal cord maximum (0.5 Gy, P = 0.004 and 0.6 Gy, P = 0.04) and volume of skin receiving ≥50 Gy (16 cm2, P = 0.01 and 19 cm2, P = 0.001). Definitively treated patients also had a reduction in mean parotid dose (0.6 Gy, P = 0.046) and volume of normal tissue receiving ≥50 Gy (67 cm3, P = 0.02). Patients with nasopharyngeal carcinoma received the greatest benefits with treatment adaptation with reduction in spinal cord maximum 1.2 Gy, mean parotid dose 1.2 Gy and parotid V26 6.3%. There was no significant benefit for adjuvant patients. Other factors associated with greater benefits were greater weight loss and greater reduction in neck separation and higher T stage.

Conclusions

There is minimal benefit to routine adaptive replanning in unselected patients, and no benefit in adjuvantly treated patients. Patients with nasopharyngeal carcinoma or with greater weight loss or reduction in neck separation did have clinically significant benefits. These patients should be targeted for adaptive strategies.

Introduction

Radiotherapy is an integral part of treatment for head and neck squamous cell carcinoma (HNSCC), both in the definitive and adjuvant settings. It is, however, associated with significant morbidity due to effects on normal tissues. Use of intensity-modulated radiotherapy, with its ability to deliver dose in a highly conformal way, allows greater normal tissue sparing than traditional three-dimensional conformal radiotherapy and improves quality of life in HNSCC patients [1]. With this highly conformal treatment there is the potential for changes in dosimetry to occur due to changes in patient anatomy during the course of therapy. It is currently not routine practice to account for these changes during treatment.

Changes in patient anatomy may occur either from a reduction in tumour bulk, weight loss or a reduction in postoperative oedema, and may vary between patients. Adaptive radiotherapy, in this context, refers to reimaging the patient during their radiotherapy course and generating a new radiotherapy plan based on this new imaging, which takes into account changes in anatomy. Decisions on whether to modify (adapt) a treatment plan during the treatment course are generally made empirically based on weight loss, change in neck separation or poor immobilisation shell fit. To date, a small number of studies investigating the benefits of adaptive radiotherapy in the treatment of HNSCC, generally in patients with marked changes in anatomy, have been carried out. These have shown an overall benefit in terms of reducing dose to normal tissues, particularly the parotid gland, and improved tumour target coverage [2], [3], [4]. However, it remains unclear whether all patients derive a significant benefit from adaptive replanning.

With this pilot study, we aimed to assess the feasibility of routinely offering adaptive radiotherapy to HNSCC patients in our department; to determine whether this results in clinically significant benefits in either tumour target coverage or normal tissue sparing; and to determine which patients receive the greatest benefit, with a view to selecting these patients for routine adaptive therapy.

Section snippets

Study Design and Eligibility

Two cohorts of patients were enrolled. Cohort 1 consisted of postoperative patients requiring adjuvant radiotherapy. Any patient receiving adjuvant radiotherapy/chemoradiotherapy was eligible. Cohort 2 consisted of patients receiving radical radiotherapy/chemoradiotherapy for HNSCC. Patients were eligible for cohort 2 if they had primary tumour size ≥3 cm on imaging or examination and/or cervical nodal lymphadenopathy ≥3 cm in size on clinical examination, and had not undergone surgery. This

Patient Demographics

The first 20 patients accrued to this ongoing pilot study, between December 2008 and February 2010, are presented for preliminary analysis. The patient and tumour characteristics are shown in Table 2.

Patient and Tumour Parameter Changes during Radiotherapy

Table 3 shows the changes in patient and plan parameters between CT1 and CT2. On average, lateral neck separation reduced by 6–7 mm (range –5 to 18 mm) between scans. The median parotid volume loss was 17.5% (range –1.0 to 46.0%) with a median reduction in PTV60/66 of 16% (range 0 to 45%) and PTV54

Discussion

We have shown a modest benefit to adaptive radiotherapy in these relatively unselected patients. For the group overall we found significant, although small, benefits to adaptive therapy with a reduced PTV D1, a reduced maximum spinal cord dose and a reduced volume of skin receiving ≥50 Gy. For definitively treated patients there were significant benefits also in a reduced mean parotid dose and volume of normal tissue outside the PTV receiving ≥50 Gy. The absolute magnitude of difference was also

Conclusion

Adaptive radiotherapy proved feasible. Modest benefits in reduction in PTV D1, low dose PTV coverage, spinal cord maximum dose and volume of skin receiving ≥50 Gy were found in this relatively unselected population. Definitively treated patients also had benefits in a reduction in mean parotid dose and the volume of normal tissue outside the PTV receiving ≥50 Gy. Patients with nasopharyngeal carcinoma, initial stage T3/4 and greater weight loss or a reduction in lateral neck separation received

Conflict Of Interest Statement

Lisa Capelle - No conflicts of interest to declare

Marc Mackenzie - No conflicts of interest to declare

Colin Field - No conflicts of interest to declare

Matthew Parliament - No conflicts of interest to declare

Sunita Ghosh - No conflicts of interest to declare

Rufus Scrimger - No conflicts of interest to declare

References (21)

There are more references available in the full text version of this article.

Cited by (67)

  • What information can we gain from performing adaptive radiotherapy of head and neck cancer patients from the past 10 years?

    2022, Cancer/Radiotherapie
    Citation Excerpt :

    Also, it has been shown that re-planning influences clinical outcomes: local control, disease free survival and overall survival. The most significant decrease in patient body weight is observed between 2–4 weeks of treatment which corresponds to 10fr–20fr [2–5,7,9,12,13,30,34,36–39], and this interval is particularly recommended for rescanning. Studies showed that spinal cord and parotids received more doses actually delivered than planned, which could be reduced by re-planning [11,28,37].

View all citing articles on Scopus
View full text